Clinical trial results:
Pharmacokinetic evaluation of moxifloxacin administered intravenously and orally in healthy volunteers who have had a gastric bypass.

Summary

EudraCT number	2010-018628-14
Trial protocol	BE
Global end of trial date	18 May 2010

Results information

Result version number	v1 (current)
This version publication date	06 December 2024
First version publication date	06 December 2024
Summary attachment (see zip file)	Publication (Publication.pdf)

Trial information

Trial identification

Sponsor protocol code	DRUG10_MOXI

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	University Hospital Ghent
Sponsor organisation address	C. Heymanslaan, Ghent, Belgium, 9000
Public contact	University Hospital Ghent, University Hospital Ghent, 32 093320530, hiruz.ctu@uzgent.be
Scientific contact	University Hospital Ghent, University Hospital Ghent, 32 093320530, hiruz.ctu@uzgent.be

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 May 2010
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	18 May 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Evaluation of the moxifloxacin plasma levels and the variability in healthy volunteers who have had a gastric bypass, after intravenous and oral administration of 400mg moxifloxacin

Protection of trial subjects:

See attachment

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 March 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 12
Worldwide total number of subjects	12
EEA total number of subjects	12

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	12
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

See attachment

Pre-assignment

Screening details:

See attachment

Period 1

Period 1 title	Overal Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

Arms

Arm title	General

Arm description:

See attachment

Arm type	Experimental
Investigational medicinal product name	moxifloxacin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

See attachment

Number of subjects in period 1	General
Started	12
Completed	12

Baseline characteristics

End points

End points reporting groups

Reporting group title	General
Reporting group description:	
See attachment	

Primary: Primary

End point title	Primary[1]
End point description:	
See attachment	
End point type	Primary
End point timeframe:	
See attachment	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: See attachment

End point values	General			
Subject group type	Reporting group			
Number of subjects analysed	12			
Units: units				
number (not applicable)	12			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]	
Timeframe for reporting adverse events:	
During the study	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	0

Frequency threshold for reporting non-serious adverse events: 0 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: See attachment

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported